Welcome to Interconnect®
At Interconnect, we provide the very best in personalized treatment support. Our dedicated Care Coordinators work with people who have been prescribed an Intercept treatment and their healthcare providers.
At Interconnect, we provide the very best in personalized treatment support. Our dedicated Care Coordinators work with people who have been prescribed an Intercept treatment and their healthcare providers.
You are now leaving Interconnect
Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.
Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.
Interconnect's website is being temporarily maintained and is no longer fully functional for enrollment purposes due to the withdrawal of OCALIVA.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.
For all other inquiries please contact: info@interceptpharma.com